ANDA 77864, held by Hikma Pharms. Sertraline Hydrochloride.
As of Nov 16, 2026, ANDA 77864 (Sertraline Hydrochloride), held by Hikma Pharms, was first approved by FDA on Aug 10, 2009, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 10, 2009 | Original application | Approved | None posted |
| Sertraline HydrochlorideEQ 25MG BASE · tablet;oral | Sertraline Hydrochloride | Discontinued |
| Sertraline HydrochlorideEQ 50MG BASE · tablet;oral | Sertraline Hydrochloride | Discontinued |
| Sertraline HydrochlorideEQ 100MG BASE · tablet;oral | Sertraline Hydrochloride | Discontinued |
| Aug 18, 2025 | Supplement 3Labeling · Standard review | Approved | None posted |
| Aug 18, 2025 | Supplement 4Labeling · Standard review | Approved | None posted |
| Aug 18, 2025 | Supplement 5Labeling · Standard review | Approved | None posted |
| Feb 21, 2020 | Supplement 2Labeling · Standard review | Approved | None posted |
| Feb 10, 2014 | Supplement 1Labeling · Standard review | Approved | None posted |
| Aug 10, 2009 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters